ClinicalTrials.gg
CompletedNCT05904600Updated Oct 30, 2026

Respiratory Muscle Training in Adults With Spinal Cord Injury

An interventional study of Respiratory muscle training and Control group in Spinal Cord Injuries, sponsored by University of Castilla-La Mancha. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Castilla-La Mancha · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2022, registered May 2023).
Updated Oct 30, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Enrollment
20th of 55
44 · median 30
Started
2022
with 6 others
No phase
34 of 59
8 open now
Registered
44th of 59
by date
Lead sponsor
4 of 59
University of Castilla-La Mancha

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 20th largest by enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2022, is one of 34 with no phase, and was the 44th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effectiveness of a programme based on inspiratory and expiratory muscle training to improve respiratory muscle strength, functional capacity and avoid pulmonary complications in adults with cervical or high dorsal spinal cord injury (C4-T6) in acute phase.

Read the detailed description

The design of the study is a randomised, triple-blind clinical trial with a control group.

The size of the sample will be 56 participants with cervical spinal cord injury and 56 with dorsal spinal cord injury. They will be randomized in two groups: experimental or control. The experimental group will perform combined inspiratory and expiratory muscle training as part of their rehabilitation programme during 6 weeks. The control group will continue their usual treatment.

Measurements will be taken at baseline, and post-intervention.

The statistical analysis will be an intention-to-treat analysis, and the data processing and analysis will be carried out with the Statistical Package for the Social Sciences (SPSS) version 24.0 for Windows (Armonk, NY: IBM Corp.).

Deviation from protocol: The initial recruitment estimates were overly optimistic. The planned sample size was 112 participants, including 56 with cervical spinal cord injury and 56 with thoracic spinal cord injury. However, the actual recruitment rate was lower than anticipated, making it unfeasible to achieve the target sample size within the planned study period. As the study was conducted at a single centre, the pool of eligible participants was limited. Furthermore, extending the recruitment period further threatened the continuity and stability of the research team. Therefore, the study was redefined as an exploratory study, and this change is reflected in the revised title and the analytical approach.

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Spinal Cord Injuries
  • Breathing exercises
  • Respiratory muscle training
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People diagnosed with spinal cord injury.
  • Over 18 years of age.
  • Time of evolution less than 6 months and at least 4 weeks after the date of injury.
  • Level of lesion between C4 and T6 and degree of involvement A or B. In case of involvement A with partial preservation zone this should not include abdominal musculature according to the international standardised classification of the American Spinal Injury Association.

Exclusion criteria

Exclusion Criteria:

  • People with chest trauma.
  • Mechanically ventilated.
  • Pregnant women.
  • Any medical or psychiatric condition that could affect the ability to complete the study.
  • Carrying a tracheostomy tube that does not tolerate occlusion.
  • People who can not sit upright.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Respiratory muscle training

    Respiratory muscle training with the Orygen-Dual Valve (Forumed S.L. ESP) and an initial load of 30% of their maximum inspiratory and expiratory pressures.

    Device: Respiratory muscle training

  • Sham comparator
    Control group

    Simulated training with the Orygen-Dual Valve (Forumed S.L. ESP), without load.

    Device: Control group

Interventions

  • DeviceRespiratory muscle training

    The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.

  • DeviceControl group

    In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.

06

What researchers measure

Primary outcomes

  1. Change in maximal expiratory pressure

    The measurement of maximum static respiratory pressures will consist of performing maximum forced inspiration and expiration manoeuvres against an occluded airway in order to measure the pressure generated in the mouth, using a manometer or a pressure transducer, since, with the glottis open, the pressure in the mouth must be equal to the alveolar pressure.

    Time frame: Change after 6 weeks of intervention compared to baseline

  2. Change in maximal inspiratory pressure

    The measurement of maximum static respiratory pressures will consist of performing maximum forced inspiration and expiration manoeuvres against an occluded airway in order to measure the pressure generated in the mouth, using a manometer or a pressure transducer, since, with the glottis open, the pressure in the mouth must be equal to the alveolar pressure.

    Time frame: Change after 6 weeks of intervention compared to baseline

Secondary outcomes

  1. Change in forced vital capacity (FVC)

    Using a spirometer, with the mouthpiece tightly sealed around the lips, the participant is asked, from the residual volume, to perform a rapid but unforced maximal inspiratory manoeuvre. With an apnoea of less than one second at total lung capacity, the participant is asked to exhale maximally, rapidly and forcibly, until the lungs are completely empty. At this point, the participant is strongly encouraged to start the manoeuvre abruptly and to prolong the exhalation long enough to reach RV.

    Time frame: Change after 6 weeks of intervention compared to baseline

  2. Change in coughing capacity

    Measurement of cough capacity will be performed by determining peak cough flow using a peak expiratory flow meter (Mini Wright flow meter; Clement Clarke International Ltd., Essex, UK).

    Time frame: Change after 6 weeks of intervention compared to baseline

  3. Change in elbow flexion strength

    In all subjects, the maximum load they can move in one repetition (1RM) in both limbs will be assessed for elbow flexion with Microfet4 dynamometer; Hoggan Health Industries, West Jordan, Utah.

    Time frame: Change after 6 weeks of intervention compared to baseline

  4. Change in shoulder flexion strength

    In all subjects, the maximum load they can move in one repetition (1RM) in both limbs will be assessed for shoulder flexion with Microfet4 dynamometer; Hoggan Health Industries, West Jordan, Utah.

    Time frame: Change after 6 weeks of intervention compared to baseline

  5. Change in number of people with respiratory complications

    Respiratory complications will be assessed by consulting the medical history.

    Time frame: Change after 6 weeks of intervention compared to baseline

  6. Change in health-related quality of life assessed by Short-Form 36 questionnaire.

    Health-related quality of life will be measured with the Short-Form 36 questionnaire, with values ranging from 0 to 100 (higher scores mean better health-related quality of life).

    Time frame: Change after 6 weeks of intervention compared to baseline

  7. Change in forced expiratory volume in the first second (FEV1)

    Using a spirometer, with the mouthpiece tightly sealed around the lips, the participant is asked, from the residual volume, to perform a rapid but unforced maximal inspiratory manoeuvre. With an apnoea of less than one second at total lung capacity, the participant is asked to exhale maximally, rapidly and forcibly, until the lungs are completely empty. At this point, the participant is strongly encouraged to start the manoeuvre abruptly and to prolong the exhalation long enough to reach RV.

    Time frame: Change after 6 weeks of intervention compared to baseline

  8. Change in cardiorespiratory fitness

    Cardiorespiratory fitness will be measured using the 6-minute wheelchair propulsion test (adapted from Bass A et al. 2020). This is a validated test to measure cardiorespiratory fitness through a submaximal exercise test where the patient performs a 25-metre figure-eight run for 6 minutes and the distance covered in that time is recorded.

    Time frame: Change after 6 weeks of intervention compared to baseline

07

Study locations

1 site
  • Sara Reina Gutiérrez
    Toledo, Toledo 45071, Spain
08

References and documents

Individual participant data

Plan to share: No — Only the research team, and the health authorities, who have a duty of confidentiality, will have access to all data collected by the study. Information that cannot be identified may be passed on to third parties.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Dec 2025, 40 months.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 40 months is close to that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2023 → Dec 2025 and completion Dec 2023 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
Jun 15, 2023
StartActual
Aug 30, 2022
Primary completionActual
Dec 30, 2025was Dec 2023
CompletionActual
Dec 30, 2025was Dec 2023
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Sara Reina Gutiérrez · Toledo, Spain
Show 1 removed
  • Sara Reina Gutiérrez · Toledo, Spain
Oct 30, 2026
Primary completion
Dec 30, 2023→Dec 30, 2025 (actual)
Oct 30, 2026
Study completion
Dec 30, 2023→Dec 30, 2025 (actual)
Oct 30, 2026
Enrollment
112 (estimated)→44 (actual)
Oct 30, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedLevel of lesion between C5C4 and D5T6 and degree of involvement A or B. In case of involvement A with partial preservation zone this should not include abdominal musculature according to the international standardised classification of the American Spinal Injury Association.
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Sara Reina Gutiérrez · Toledo, Spain
    Show 1 removed
    • Sara Reina Gutiérrez · Toledo, Spain
    Primary completion Dec 30, 2023→Dec 30, 2025 (now actual)
    Study completion Dec 30, 2023→Dec 30, 2025 (now actual)
    Enrollment 112 (estimated)→44 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedLevel of lesion between C5C4 and D5T6 and degree of involvement A or B. In case of involvement A with partial preservation zone this should not include abdominal musculature according to the international standardised classification of the American Spinal Injury Association.
    + 5 other changes: identifiers, verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05904600
Collaborators
Hospital Nacional de Parapléjicos de Toledo
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Aug 30, 2022
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Oct 30, 2026

Study contacts

Ana Torres-Costoso
principal investigator · University of Castilla-La Mancha

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion